Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Liver-directed therapy

5 evidence topics · 5 sources

Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases

“Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After the first HAE, median HFS was 14.5 months, and median OS was 16 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“IV fluids containing dextrose given preprocedurally in 85% (n = 17) of patients were stopped either immediately postprocedure, on resumption of oral intake, or before discharge, in all patients after the first HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote